MedPath

CELGENE CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Phase 2
Completed
Conditions
Crohn's Disease
Interventions
First Posted Date
2015-08-24
Last Posted Date
2021-01-22
Lead Sponsor
Celgene
Target Recruit Count
69
Registration Number
NCT02531113
Locations
🇨🇦

LHSC Victoria Hospital, London, Ontario, Canada

🇺🇸

IMIC, Inc., Palmetto Bay, Florida, United States

🇺🇸

DM Clinical Research, Oak Lawn, Illinois, United States

and more 25 locations

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2015-08-24
Last Posted Date
2025-01-22
Lead Sponsor
Celgene
Target Recruit Count
878
Registration Number
NCT02531126
Locations
🇺🇸

Local Institution - 102, Anaheim, California, United States

🇺🇸

Local Institution - 179, Germantown, Tennessee, United States

🇺🇸

Local Institution - 143, Portland, Oregon, United States

and more 25 locations

An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.

Completed
Conditions
Multiple Myeloma
First Posted Date
2015-08-19
Last Posted Date
2020-05-27
Lead Sponsor
Celgene
Target Recruit Count
238
Registration Number
NCT02528838

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2015-08-13
Last Posted Date
2019-11-08
Lead Sponsor
Celgene
Target Recruit Count
28
Registration Number
NCT02521714
Locations
🇺🇸

Covance-Daytona Beach, Daytona Beach, Florida, United States

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Phase 1
Completed
Conditions
Pulmonary Fibrosis
Interventions
First Posted Date
2015-07-29
Last Posted Date
2017-04-04
Lead Sponsor
Celgene
Target Recruit Count
16
Registration Number
NCT02510937
Locations
🇺🇸

LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States

🇺🇸

Tampa General Hospital, Tampa, Florida, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 3 locations

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Phase 1
Completed
Conditions
Lymphoma, Non-Hodgkin
Interventions
First Posted Date
2015-07-27
Last Posted Date
2023-09-08
Lead Sponsor
Celgene
Target Recruit Count
15
Registration Number
NCT02509039
Locations
🇯🇵

Local Institution - 003, Chikusa-ku, Japan

🇯🇵

Local Institution - 001, Kashiwa, Japan

🇯🇵

Local Institution - 002, Koto-ku, Tokyo, Japan

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Phase 1
Terminated
Conditions
Healthy Volunteers
Parapsoriasis
Interventions
Drug: Placebo
First Posted Date
2015-07-20
Last Posted Date
2019-11-18
Lead Sponsor
Celgene
Target Recruit Count
24
Registration Number
NCT02502188
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2
Completed
Conditions
Hematologic Malignancies
Neoplasms
Hematologic Neoplasm
Interventions
First Posted Date
2015-07-10
Last Posted Date
2025-05-22
Lead Sponsor
Celgene
Target Recruit Count
5
Registration Number
NCT02494258
Locations
🇺🇸

Local Institution - 101, Gainesville, Florida, United States

🇺🇸

Local Institution - 103, Baltimore, Maryland, United States

🇺🇸

Local Institution - 102, Houston, Texas, United States

and more 1 locations

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Phase 2
Completed
Conditions
Leukemia, Myeloid, Acute
Interventions
Other: Control Arm
First Posted Date
2015-05-21
Last Posted Date
2019-12-20
Lead Sponsor
Celgene
Target Recruit Count
7
Registration Number
NCT02450877
Locations
🇩🇪

Charite Berlin, Berlin, Germany

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇪

Universitatsklinikum Essen, Essen, Germany

and more 5 locations

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Phase 2
Completed
Conditions
Leukemia, Myelomonocytic, Juvenile
Myelodysplastic Syndrome
Interventions
First Posted Date
2015-05-19
Last Posted Date
2019-07-11
Lead Sponsor
Celgene
Target Recruit Count
28
Registration Number
NCT02447666
Locations
🇧🇪

Hopital Universitaire des Enfants, Brussels, Belgium

🇨🇭

Universitäts-Kinderklinik, Zurich, Switzerland

🇳🇱

Erasmus University Medical Center, Rotterdam, Netherlands

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath